Depletion of Omega-3 Fatty Acid Levels in Red Blood Cell Membranes of Depressive Patients

Peet, Malcolm; Murphy, Brendan; Shay, Janet; Horrobin, David F.

doi:10.1016/s0006-3223(97)00206-0

Cited by 516 publications

(302 citation statements)

References 38 publications

Supporting

Mentioning

267

Contrasting

Unclassified

Order By: Relevance

“…Previous studies reported that levels of EPA and DHA in serum or in the red blood cell membrane were lower in subjects with major depression than in healthy controls (Edwards et al, 1998;Peet et al, 1998;Maes et al, 1999). In the present study, there were no differences in the levels of DHA and EPA in serum phospholipids between subjects with major depression and subjects without depression.…”

Section: Serum Fatty Acid and Depression In Cancer Patients M Kobayakcontrasting

confidence: 64%

“…However, subjects with depression had significantly lower intake of ALA, which was a major dietary omega-3 FA (Suzuki et al, 2004). As ingested ALA can be converted into EPA and DHA in vivo, the result of our previous study (Suzuki et al, 2004) did not seem to be inconsistent with the studies indicating lower levels of EPA and DHA in phospholipids in depression (Edwards et al, 1998;Peet et al, 1998;Maes et al, 1999). Then, in the present study, we hypothesised that lower levels of EPA and DHA in serum phospholipids were associated with major depression and minor depression in lung cancer patients.…”

Section: Serum Fatty Acid and Depression In Cancer Patients M Kobayakmentioning

confidence: 65%

“…Docosahexaenoic acid (DHA), one of the omega-3 fatty acids (FAs), is a major component of membrane FAs in brain neural cells and lack of DHA has been shown to alter neural transmission in animal studies (Bruinsma and Taren, 2000;Innis, 2000;Ng and Innis, 2003). Previous studies have shown associations between DHA or its precursor, eicosapentaenoic acid (EPA, omega-3 FA), and major depression in subjects without cancer (Edwards et al, 1998;Hibbeln, 1998;Peet et al, 1998;Maes et al, 1999). Other studies have shown their possible therapeutic potential with few adverse effects in clinical trials (Nemets et al, 2002;Peet and Horrobin, 2002;Su et al, 2003).…”

mentioning

confidence: 99%

See 2 more Smart Citations

Levels of omega-3 fatty acid in serum phospholipids and depression in patients with lung cancer

et al. 2005

View full text Add to dashboard Cite

Previous studies suggested that omega-3 fatty acids (FAs) have therapeutic effects against depression, but there is no evidence in the oncological setting. Our preliminary study reported the association between lower omega-3 FA intake and occurrence of depression in lung cancer patients. To explore the association further, the present study examined whether depression was associated with lower levels of omega-3 FAs in serum phospholipids. A total of 717 subjects in the Lung Cancer Database Project were divided into three groups by two cutoff points of the Hospital Anxiety and Depression Scale depression subscale (HADS-D). In all, 81 subjects of the nondepression and minor depression groups (HADS-Do5 and 5pHADS-Dp10, respectively) were selected to match with 81 subjects of the major depression group (HADS-D410) for age, gender, clinical stage, and performance status. Fatty acids were assayed by gas chromatography and compared among the three matched groups. There were no differences between the major depression group and nondepression group in any FAs. The minor depression group had higher mean levels of docosahexaenoic acid (mean7s. Major and minor depressions are one of the most common psychiatric problems in clinical oncological settings (Derogatis et al, 1983;Razavi and Stiefel, 1994;McDaniel et al, 1995). Docosahexaenoic acid (DHA), one of the omega-3 fatty acids (FAs), is a major component of membrane FAs in brain neural cells and lack of DHA has been shown to alter neural transmission in animal studies (Bruinsma and Taren, 2000;Innis, 2000;Ng and Innis, 2003). Previous studies have shown associations between DHA or its precursor, eicosapentaenoic acid (EPA, omega-3 FA), and major depression in subjects without cancer (Edwards et al, 1998;Hibbeln, 1998;Peet et al, 1998;Maes et al, 1999). Other studies have shown their possible therapeutic potential with few adverse effects in clinical trials (Nemets et al, 2002;Peet and Horrobin, 2002;Su et al, 2003). In the oncological setting, the use of antidepressants has been limited due to their adverse effects (Akizuki et al, 2002;Fisch, 2004). In our previous pilot study to obtain information for planning interventional research, depression in cancer patients was not associated with either EPA or DHA intakes, but was associated with lower intake of alpha-linolenic acid (ALA: major omega-3 FAs in diet, precursor of EPA and DHA) (Suzuki et al, 2004). To elucidate any such association in detail, the present study was designed to examine our hypothesis that lower levels of omega-3 FAs (EPA, DHA) in serum phospholipids are associated with major and minor depression in lung cancer patients. MATERIALS AND METHODS Study design and subjectsThe present study was a three matched group case -control study, based in part on the Lung Cancer Database Project, which was a prospective cohort study for investigation of the pathogenesis of and development of new therapy for lung cancer at the National Cancer Center Hospital East and the National Cancer Center Research Institute East, ...

show abstract

Section: Serum Fatty Acid and Depression In Cancer Patients M Kobayakcontrasting

confidence: 64%

Section: Serum Fatty Acid and Depression In Cancer Patients M Kobayakmentioning

confidence: 65%

mentioning

confidence: 99%

See 1 more Smart Citation

Levels of omega-3 fatty acid in serum phospholipids and depression in patients with lung cancer

et al. 2005

View full text Add to dashboard Cite

show abstract

“…Epidemiological findings linking depression and low levels of fish intake have been reported (Hibbeln, 1998;Tanskanen et al, 2001), and biochemical research has also shown that the concentrations of each o-3 FA are significantly lower in the serum or red blood cell membranes of depressed patients than in control subjects (Edwards et al, 1998;Peet et al, 1998;Maes et al, 1999). Ethyl-EPA augmentation therapy has been reported to improve depressive symptoms in patients with major depression in randomised placebo-controlled double-blind clinical trials (Nemets et al, 2002;Peet and Horrobin, 2002) and in one clinical report (Puri et al, 2002).…”

mentioning

confidence: 98%

Daily omega-3 fatty acid intake and depression in Japanese patients with newly diagnosed lung cancer

et al. 2004

View full text Add to dashboard Cite

The aim of the present study was to examine the association between daily omega-3 fatty acid intake and depression in Japanese cancer patients. Omega-3 fatty acid intake in 771 patients with newly diagnosed primary lung cancer was evaluated using a foodfrequency questionnaire, and the prevalence of depression was examined using the cutoff values for the depression subscale included in the Hospital Anxiety and Depression Scale. After adjustment for potential confounding factors, the odds ratio (OR) for depression among patients in the highest quartile of the total eicosapentaenoic acid-(C20:5n-3) and docosapentaenoic acid (C22:6n-3)-intake group compared with patients in the lowest quartile was not significantly different. On the other hand, the OR among the highest quartile of a-linolenic acid (C18:3n-3) intake (adjusted OR ¼ 0.50, 95% CI: 0.31 -0.71, P for trend ¼ 0.004) and the highest quartile of total omega-3 fatty acid intake (adjusted OR ¼ 0.55, 95% CI: 0.35 -0.88, P for trend ¼ 0.022) were significantly different. These results suggest that total eicosapentaenoic acid and docosapentaenoic acid intake might not be associated with depression in Japanese patients with newly diagnosed lung cancer, but that a-linolenic acid intake and total omega-3 fatty acid intake might be.

show abstract

“…There is also evidence that n-3 PUFA are of therapeutic benefit as an adjunctive treatment in depression (13 -15) . Meta-analyses of clinical trials (16,17) have shown a moderate anti-depressant effect of DHA and/or EPA, in addition to anti-depressant medication, after [4][5][6][7][8][9][10][11][12][13][14][15][16] weeks of treatment. However, there was substantial heterogeneity among trials, and several double-blind randomised controlled trials (18 -20) found no beneficial effect of n-3 PUFA on depression.…”

mentioning

confidence: 99%

The efficacy of n-3 fatty acids DHA and EPA (fish oil) for perinatal depression

2010

View full text Add to dashboard Cite

Depressive symptoms are common during pregnancy and the post-partum period. Although essential n-3 PUFA may have beneficial effects on depression, it remains unclear whether they are also effective for perinatal depression. The purpose of the present study was to assess the efficacy of n-3 supplementation for perinatal depression, by performing a meta-analysis on currently available data. After a thorough literature search, we included seven randomised controlled trials in the meta-analysis, all with EPA and/or DHA supplementation. Most studies were judged to be of low-to-moderate quality, mainly due to small sample sizes and failure to adhere to Consolidated Standards of Reporting Trials guidelines. Some studies were not primarily designed to address perinatal depression. A total of 309 women on n-3 fatty acid supplementation were compared with 303 women on placebo treatment. n-3 Supplementation was not found to be significantly more effective than placebo at post-treatment with a pooled effect size (Hedges's g) of 20·03 (95 % CI 2 0·18, 0·13; P¼ 0·76) using a fixed-effects model. Heterogeneity was low-to-moderate (I 2 ¼ 30 %). In a subgroup analysis of three small studies of pregnant women with major depression, there was some indication of effectiveness (effect size 0·17; 95 % CI 2 0·21, 0·55). In conclusion, the question of whether EPA and DHA administration is effective in the prevention or treatment of perinatal depression cannot be answered yet. Future research should focus on women who are clinically depressed (or at risk). The quality of research in this area needs to improve.

show abstract

Depletion of Omega-3 Fatty Acid Levels in Red Blood Cell Membranes of Depressive Patients

Cited by 516 publications

References 38 publications

Levels of omega-3 fatty acid in serum phospholipids and depression in patients with lung cancer

Levels of omega-3 fatty acid in serum phospholipids and depression in patients with lung cancer

Daily omega-3 fatty acid intake and depression in Japanese patients with newly diagnosed lung cancer

The efficacy of n-3 fatty acids DHA and EPA (fish oil) for perinatal depression

Contact Info

Product

Resources

About